Cancer

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Thursday, April 4, 2024
Risk, Sensei, Patient, Research, Tumor microenvironment, Manuscript, CRS, Cancer, Trial of the century, Cytokine release syndrome, Myelocyte, Antibody, Safety, Therapy, VISTA, Nature Communications, PD-1, Vaccine

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

Lirum Therapeutics to Present Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against Adult and Pediatric IGF-Related Cancers, at the 2024 AACR Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Malignancy, Head, Neuroblastoma, Section 23, Breast, Sarcoma, AACR, Therapy, Cancer, Poster, Neck

Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.

Key Points: 
  • Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement.
  • In particular, these malignancies have known genetic alterations affecting the IGF-1R pathway and/or high IGF-1R expression tied to poor outcomes.
  • Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway.
  • Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, Georgia State University, Messenger, Death, Doctor of Philosophy, SARS-CoV-2, Capsid, ACE2, Combat, Infection, Cancer, Omicron, Vaccine, Antigen

ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC.

Key Points: 
  • During his presentation, titled “Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to Combat SARS-CoV-2 Variation”, Dr. Newman described GeoVax’s development program for GEO-CM04S1.
  • The data presented were generated in collaboration with scientists at Georgia State University using the human ACE2 transgenic mice, one of the “gold standard” small animal models used for studying Covid vaccines.
  • GEO-CM04S1 incorporates both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce broadly specific antibody and T cell responses.
  • I anticipate similar findings will be observed in our Phase 2 clinical trials as the studies are unblinded later this year.”

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, April 4, 2024
Fulvestrant, KICKSTART, Survival, NSCLC, AML, Patient, Acute myeloid leukemia, Cancer, Hope, Pembrolizumab, Lung cancer, Therapy, Breast cancer, Safety, Cox, PFS, Interval (mathematics), Effector, Pharmaceutical industry

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.

Key Points: 
  • The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of p≤0.2.
  • The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively.
  • There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.
  • “We sincerely appreciate the contributions of all the patients, their families, and trial site professionals who contributed to the execution of the trial.

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Retrieved on: 
Thursday, April 4, 2024
HCC, Combination therapy, Nivolumab, Head, Patient, Bevacizumab, Therapy, Cancer, PD-1, Pharmaceutical industry

These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.

Key Points: 
  • These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.
  • “In this Phase 1 study of TPST-1120, we saw the first evidence of anti-tumor activity in multiple cancer types, affirming our belief that PPARα inhibition is an exciting and novel approach for cancer treatment,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • “These early-phase data are supported by the positive top line results of the ongoing randomized Phase 1b/2 trial in first-line HCC.
  • We believe there is tremendous potential for TPST-1120 to make a meaningful impact for patients and we look forward to providing updated data this year.”

HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

Retrieved on: 
Thursday, April 4, 2024
Princess Margaret Cancer Centre, Lung cancer, Data science, Real, Patient, Research, Cancer, AI, Oncology, TSX, Language, Data, Artificial intelligence, Health, AIDX, Medical device

Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.

Key Points: 
  • Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.
  • TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce its subsidiary Pentavere Research Group (“Pentavere”) has achieved a significant milestone with the publication of a paper validating the use of generative AI to identify rare lung cancer patients.
  • We’ve developed best in class AI that is core to our mission of preventative care.
  • This milestone validates the power of fine-tuned generative AI to drive meaningful insights and transform patient care.

New Survey Reveals Present-Day Risks of Asbestos Exposure in America - 38% in High-Risk Jobs, 47% Vulnerable through Second-Hand Exposure

Retrieved on: 
Thursday, April 4, 2024
Law, Asbestos, Risk, Education, Lung, Public, PLLC, Cancer, Mesothelioma, EPA, Sickness, Gen

These findings, released today, underscore the urgent necessity for Asbestos Cancer Risk Awareness and routine testing.

Key Points: 
  • These findings, released today, underscore the urgent necessity for Asbestos Cancer Risk Awareness and routine testing.
  • They emphasize the crucial importance of proactive measures to mitigate the pervasive risks associated with asbestos exposure in the United States.
  • Awareness about the risks of asbestos exposure appears to be widespread, with 45% of respondents acknowledging the potential dangers.
  • For more information on asbestos risks and testing, including an infographic, podcast, and video, visit this page .

Central Georgia Cancer Care Joins American Oncology Network to Elevate Local Cancer Care Delivery

Retrieved on: 
Thursday, April 4, 2024
AON, Hospice, Partnership, Physician, Patient, Running, Cancer, MD, Clinical trial, Warner Robins, Georgia, Health, Rehabilitation, Nursing

Central Georgia Cancer Care is a nationally recognized independent oncology practice known for providing personalized care close to home.

Key Points: 
  • Central Georgia Cancer Care is a nationally recognized independent oncology practice known for providing personalized care close to home.
  • To ensure seamless care, we've joined forces with the American Oncology Network, providing access to additional resources, support and experts.
  • “Central Georgia Cancer Care has been a cornerstone in the community for cancer patients for over 40 years, providing compassionate and personalized care and treatment plans to every patient who walks into the clinics.
  • “Community practices that deliver critical care services, treatments and therapies help keep cancer care local and affordable for patients.

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Journal, Therapy, Biology, Cancer, AAI

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.
  • “We are thrilled to be attending and presenting for the first time at AAI to highlight the data supporting the potential of our novel platform in immunology-based diseases beyond cancer,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
  • “While our core focus remains rooted in oncology, we understand that the biology driving our PREDATOR platform is also capable of targeting immunology targets, and this data validates the potential utility in broader therapeutic areas.
  • It’s a pivotal moment as we step into the immunology landscape, ready to showcase our innovative contributions and engage with fellow leaders in the field.”
    Details for the poster presentation is as follows: